Structure Therapeutics (GPCR) Cash & Equivalents (2022 - 2026)

Structure Therapeutics' Cash & Equivalents history runs 5 years deep, the most recent figure standing at $1.5 billion for Q1 2026.

• In Q1 2026, Cash & Equivalents rose 77.02% year-over-year to $1.5 billion; the TTM figure through Mar 2026 stood at $1.5 billion (up 77.02% YoY), while the FY2025 annual figure was $799.6 million, down 8.65% from the prior year.
• Cash & Equivalents was $1.5 billion for Q1 2026 at Structure Therapeutics, up from $799.6 million in the prior quarter.
• In the past five years, Cash & Equivalents ranged from a high of $1.5 billion in Q1 2026 to a low of $26.1 million in Q4 2022.
• Historically, Cash & Equivalents has averaged $546.2 million across 5 years, with a median of $614.0 million in 2024.
• The sharpest annual moves came in 2024 and 2025: Cash & Equivalents jumped 2184.0% in 2024, then plunged 84.14% in 2025.
• A 5-year view of Cash & Equivalents shows it stood at $26.1 million in 2022, then surged by 397.46% to $129.8 million in 2023, then soared by 574.41% to $875.3 million in 2024, then declined by 8.65% to $799.6 million in 2025, then surged by 82.4% to $1.5 billion in 2026.
• The last three Cash & Equivalents figures came in at $1.5 billion (Q1 2026), $799.6 million (Q4 2025), and $791.6 million (Q3 2025), per Business Quant data.